Indivior Pharmaceuticals, Inc. - 8-K Filing

Indivior Pharmaceuticals agreed to voluntarily supplement proxy/prospectus disclosures related to its merger with Supernus after shareholder complaints.

SEC EDGAR ·

Tickers: $INDV

Read the full article at SEC EDGAR

More Regulatory news